This analysis examines the outlook for companies in Datamonitor's Emerging Pharma & Biotech peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered.
Features and benefits
Highlights
Strategic insight into the prospects for a selection of Emerging Pharma & Biotech companies over the next six years. Picking out key trends across the companies and identifying key catalysts for 2012.
Table of Contents
INTRODUCTION
Data sourcing
(Untitled sub-section)
Further reading
EXECUTIVE SUMMARY
Key findings
EMERGING PHARMA AND BIOTECH OUTLOOK
Emerging Pharma and Biotech prescription pharma sales performance, 2010–16
Therapy area analysis
Disease area analysis
Molecule type analysis
KEY 2012 EMERGING PHARMA AND BIOTECH CATALYSTS
Company catalysts
Amylin/Alkermes
Auxilium
BioMarin
Dendreon
Exelixis
Human Genome Sciences
Incyte
Ironwood
ISIS
Keryx
Map
Medivation
NPS
Onyx
Optimer/Cubist
Protalix
Regeneron
Savient
Seattle Genetics
United Therapeutics
Vertex
Vivus
APPENDIX
References
Datamonitor reports
Exchange rates
List of Tables
Table: Overview of Emerging Pharma and Biotech peer set
Table: Exchange rates, 2011
List of Figures
Figure: The PharmaVitae Explorer
Figure: Emerging Pharma and Biotech prescription pharma sales ($bn) and growth rate (%), 2010–16
Figure: Emerging Pharma and Biotech prescription pharma sales by company ($bn), 2016
Figure: Prescription pharmaceutical sales by therapy area ($bn), 2004–16
Figure: Sales growth by launch/core/expiry by therapy area ($bn), 2010–16
Figure: Prescription pharma sales by leading disease area ($bn), 2010–16
Figure: Sales growth in key emerging pharma and biotech disease areas, emerging players versus the top 50 ($bn), 2010–16
Figure: Prescription pharma sales by molecule type ($bn), 2010–16
Request a Sample or Buy your copy of the report @ http://www.reportsnreports.com/reports/144095-emerging-pharma-biotech-company-outlook-to-2016.html
